| CAS NO: | 2438-72-4 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| 2g | 电议 |
| 5g | 电议 |
| 10g | 电议 |
| 25g | 电议 |
| Molecular Weight (MW) | 223.27 |
|---|---|
| Formula | C12H17NO3 |
| CAS No. | 2438-72-4 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 45 mg/mL (201.5 mM) |
| Water: <1 mg/mL | |
| Ethanol: 3 mg/mL (13.4 mM) | |
| Other info | Chemical Name: 2-(4-butoxyphenyl)-N-hydroxyacetamide InChi Key: MXJWRABVEGLYDG-UHFFFAOYSA-N InChi Code: InChI=1S/C12H17NO3/c1-2-3-8-16-11-6-4-10(5-7-11)9-12(14)13-15/h4-7,15H,2-3,8-9H2,1H3,(H,13,14) SMILES Code: O=C(NO)CC1=CC=C(OCCCC)C=C1 |
| Synonyms | CP 1044 J 3; Bufexamic acid; CP-1044-J-3; CP1044J3; Droxaryl; Parfenac |
| In Vitro | In vitro activity: Bufexamac is a specific inhibitor of class IIB histone deacetylases (HDAC6 and HDAC10). Treatment of peripheral blood mononuclear cells with bufexamac inhibits the secretion of IFN-α. Bufexamac is a frequent and relevant contact sensitizer. Bufexamac is a non-steroidal anti-inflammatory drug. |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Nat Biotechnol. 2011 Mar;29(3):255-65. |
m.cnreagent.com